Enjosim Medical secures series A funding to boost injection pen capacity

Recently, Shanghai Enjosim Medical Technology Co., Ltd. ("Enjosim"), a leading player in China's self-administration system industry, has completed an A-round financing of tens of millions of yuan. This is the second financing completed by the company this year, with a total financing of nearly 150 million yuan. 

This round of financing was led by Moutai Fund, with follow-up investments from existing shareholders Lightspeed China Partners, Yinman Capital, and Grandway Capital. The rapid completion of two rounds of financing within the year not only marks the market's recognition of  Enjosim's strong capabilities and broad prospects in the self-administration system field but also injects robust momentum into the company's future development. 

According to the company, the proceeds will be primarily allocated to the construction of its new production base. This includes fitting out a new R&D and production complex, installing multiple automated production lines and injection molding equipment, and funding R&D for new products. 

Enjosim has broken ground on a new production base for high-precision pen injectors. By integrating globally advanced mold equipment, high-precision injection molding processes, and fully automated assembly technology, the project aims to establish a production base for high-precision pen injectors compatible with biologics such as insulin, GLP-1, and growth hormones. Additionally, continuous research and development will focus on energy-storing injection pens, smart injection pens, wearable patch pumps, inhalation drug delivery devices, and microneedle injection devices. 

The new production base is expected to be commissioned in 2025, with an annual capacity of over 50 million units when operating at full capacity, further meeting the continuously growing global demand for self-administration systems.

Since its inception, Enjosim has been dedicated to the R&D, manufacturing, and commercialization of self-administration systems, with a specific focus on those for large-molecule biologics. Its commercial portfolio comprises a range of high-precision pen injectors for drugs including insulin, GLP-1 agonists, growth hormone, and follicle-stimulating hormone. The company has also forged solid partnerships with over 20 leading pharmaceutical manufacturers worldwide. 

Enjosim  is headquartered in Shanghai, with an industrial factory covering an area of over ten thousand square meters. It is equipped with automated production lines and a Class 100,000 clean assembly workshop. The company also has an independent mold processing factory and plastic injection molding factory for components, enabling integrated, full-process supporting production services for subcutaneous drug delivery devices, from R&D design, mold processing, injection molding to large-scale product assembly. 

Enjosim's core technical team has over 10 years of experience in the research, development, and production of injection pens, with strong R&D capabilities and extensive experience in the registration of drug-device combination products. After the completion of this round of financing, Enjosim will continue to deepen its expertise in the self-administration systems field, actively support Chinese pharmaceutical companies in expanding overseas, and provide global patients with more convenient and efficient self-administration solutions, leading continuous innovation and development in the self-administration systems industry.